ACETAMINOPHEN AND IBUPROFEN

Post-LOESM

acetaminophen and ibuprofen

Aurobindo Pharma

ANDAORALTABLET

Approved

Aug 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ACETAMINOPHEN AND IBUPROFEN (acetaminophen and ibuprofen) by Aurobindo Pharma is cyclooxygenase inhibitors [moa]. Approved for minor aches, pains due to: headache toothache backache menstrual cramps muscular aches minor pain of arthritis. First approved in 2023.

Drug data last refreshed 21h ago

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (2)

minor aches pains due to: headache toothache backache menstrual cramps muscular aches minor pain of arthritis

Worked on ACETAMINOPHEN AND IBUPROFEN at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.